AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer
Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.